Rate Video

ESMO 2018 | Limiting duration of treatment with checkpoint inhibitors: the data

Bladder Cancer Lung Cancer Melanoma Atezolizumab Ipilimumab Nivolumab Pembrolizumab

CheckMate 153 KEYNOTE-001 KEYNOTE-006

Jeffrey Weber, MD, PhD, of the Perlmutter Cancer Center, New York, NY, discusses the latest clinical trials and explores the comparative efficacy of single agent and combination therapy for melanoma involving checkpoint inhibitors. Dr Weber concludes the interview, indicating the application of a Positron Emission Tomography (PET) scan in patients 1-2 years into checkpoint inhibitor therapy, to determine the safety of the treatment. This interview was recorded at the European Society for Medical Oncology (ESMO) 2018 Congress, in Munich, Germany.

What can be achieved with triple combination therapy Phase I trial for metastatic melanoma

Jeffrey Weber • 31 Aug 2016

Clinical trials investigating the management of immune-related adverse events

Jeffrey Weber • 20 May 2022

Novel biomarkers of response to ICI in melanoma

Jeffrey Weber • 20 Apr 2023

Clinical trials investigating the treatment of melanoma

Jeffrey Weber • 20 Apr 2022

Related Videos

FGFR driver genetic alterations in NSCLC

Shirish Gadgeel

‘It’s all about checkpoint inhibitors’ – Rob Jones on bladder cancer during ASCO 2017

Immunotherapy in second-line treatment of non-small cell lung cancer

How the AURA3 trial has changed conversations about re-biopsy in second-line lung cancer treatment